1.
Costa e Silva JA. Evidence-based analysis of the worldwide abuse of licit and illicit drugs. Hum Psychopharmacol. 2002;17(3):131-40. doi: 10.1002/hup.378. [PubMed: 12404690].
2.
Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085-99. doi: 10.1111/j.1360-0443.2009.02564.x. [PubMed: 19426289].
3.
United Nations Office on Drugs and Crime (UNODC) . World Drug Report 2010. United Nations publication, Sales No E.10.XI.13; 2010.
4.
United Nations Office on Drugs and Crime (UNODC) . World Drug Report 2014. United Nations publication, Sales No. E.14.XI.7; 2014.
5.
Moharreri MR. The International Challenge of Drug Abuse. General view of drug abuse in Iran, and a one-year report of out- patient treatment of opiate addiction in the city of Shiraz. Rockville: NIDA Research Monograph 19; 1978.
6.
Narenjiha H, Rafiey H, Baghestani AH. Rapid situation assessment of drug abuse and drug dependence in Iran. Tehran: Darius Institute; 2005.
7.
Barooni S, Mehrdad R, Akbari E. A survey of Ecstasy use among 15-25 year-olds in five areas of Tehran [In Persian]. Tehran Univ Med J. 2008;65(11):49-54.
8.
Mohtasham-Amiri Z, Jafari-Shakib A, Khalili-Moosavi A. Prevalence and factors associated with Ecstasy use among college undergraduates in north of Iran-2005. Asian J Psychiatr. 2011;4(1):31-4. doi: 10.1016/j.ajp.2011.01.004. [PubMed: 23050911].
9.
Moasheri N, Miri M, Mashreghi Moghadam HM, Eslami MR. A Study of Birjand University students' knowledge and attitude towards taking Ecstasy pills [In Persian]. J Birjand Univ Med Sci. 2007;13(4):9-15.
10.
Barati M, Allahverdipour H, Jalilian F. Prevalence and predictive factors of psychoactive and hallucinogenic substance abuse among college students [In Persian]. J Fund Ment Health. 2012;13(4):347-83.
11.
Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann N Y Acad Sci. 2004;1025:446-57. doi: 10.1196/annals.1316.055. [PubMed: 15542748].
12.
Samii AW. Drug abuse: Iran's 'thorniest problem'. Brown J World Aff. 2003;9(2):283.
13.
Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol. 1998;132(2):227-37. doi: 10.1080/00223989809599162. [PubMed: 9529666].
14.
Brecht ML, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoactive Drugs. 2000;32(2):211-20. doi: 10.1080/02791072.2000.10400231. [PubMed: 10908010].
15.
Koob GF, Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3113-23. doi: 10.1098/rstb.2008.0094. [PubMed: 18653439].
16.
Newton TF, De La Garza R2, Kalechstein AD, Tziortzis D, Jacobsen CA. Theories of addiction: methamphetamine users' explanations for continuing drug use and relapse. Am J Addict. 2009;18(4):294-300. doi: 10.1080/10550490902925920. [PubMed: 19444733].
17.
Robinson TE, Berridge KC. Review. The incentive sensitization theory of addiction: some current issues. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507):3137-46. doi: 10.1098/rstb.2008.0093. [PubMed: 18640920].
18.
Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003;6(4):347-52. doi: 10.1017/S1461145703003675. [PubMed: 14604449].
19.
Klee H. Amphetamine Misuse. Amphetamine misusers in contemporary Britain: The emergence of a hiddenpopulation: International Perspectiveson Current trends. In: Klee H, editor. Amsterdam: Harwood Academic Publishers; 1997.
20.
Gossop MR, Bradley BP, Brewis RK. Amphetamine withdrawal and sleep disturbance. Drug Alcohol Depend. 1982;10(2-3):177-83. doi: 10.1016/0376-8716(82)90010-2. [PubMed: 7166130].
21.
Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry. 1999;33(1):89-93. doi: 10.1046/j.1440-1614.1999.00517.x. [PubMed: 10197890].
22.
Churchill AC, Burgess PM, Pead J, Gill T. Measurement of the severity of amphetamine dependence. Addiction. 1993;88(10):1335-40. doi: 10.1111/j.1360-0443.1993.tb02019.x. [PubMed: 8251870].
23.
McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100(9):1320-9. doi: 10.1111/j.1360-0443.2005.01160.x. [PubMed: 16128721].
24.
McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat. 2008;34(4):443-9. doi: 10.1016/j.jsat.2007.05.007. [PubMed: 17629443].
25.
World Health Organization . Process of translation and adaptation of instruments. World Health Organization; 2010.
26.
Waltz CF, Strickland OL, Lenz ER. Measurement in nursing and health research. Springer Publishing Company; 2010.
27.
Bagheri M, Mokri A, Khosravi A, Kabir K. Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community. Int J High Risk Behav Addict. 2015;4(3). e23903. doi: 10.5812/ijhrba.23903. [PubMed: 26495258].
28.
Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010;105(10):1809-18. doi: 10.1111/j.1360-0443.2010.03066.x. [PubMed: 20840201].
29.
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus. 2008;29(3):31-49. doi: 10.1080/08897070802218554. [PubMed: 19042205].
30.
Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001;63(3):269-76. doi: 10.1016/S0376-8716(00)00217-9. [PubMed: 11418231].
31.
Rawson RA, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, et al. Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis. 2002;21(1):107-19. doi: 10.1300/J069v21n01_09. [PubMed: 11831496].
32.
Watson R, Hartmann E, Schildkraut JJ. Amphetamine withdrawal: affective state, sleep patterns, and MHPG excretion. Am J Psychiatry. 1972;129(3):263-9. doi: 10.1176/ajp.129.3.263. [PubMed: 4340897].
33.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict. 2008;17(1):24-7. doi: 10.1080/10550490701756070. [PubMed: 18214719].
34.
Leventhal AM, Kahler CW, Ray LA, Stone K, Young D, Chelminski I, et al. Anhedonia and amotivation in psychiatric outpatients with fully remitted stimulant use disorder. Am J Addict. 2008;17(3):218-23. doi: 10.1080/10550490802019774. [PubMed: 18463999].
LEAVE A COMMENT HERE: